Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans

被引:108
|
作者
Schmajuk, Gabriela [1 ]
Trivedi, Amal N. [2 ]
Solomon, Daniel H. [3 ]
Yelin, Edward [4 ]
Trupin, Laura [4 ]
Chakravarty, Eliza F. [1 ]
Yazdany, Jinoos [4 ]
机构
[1] Stanford Univ, Dept Med, Div Rheumatol, Stanford, CA 94304 USA
[2] Brown Univ, Dept Community Hlth & Med, Providence, RI 02912 USA
[3] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02115 USA
[4] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA USA
来源
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
QUALITY-OF-CARE; HEALTH PLANS; DISPARITIES; OUTCOMES; DATABASE; COST; BENEFICIARIES; NEIGHBORHOOD; MEDICATIONS; AMERICAN;
D O I
10.1001/jama.2011.67
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context In 2005, the Healthcare Effectiveness Data and Information Set (HEDIS) introduced a quality measure to assess the receipt of disease-modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA). Objective To identify sociodemographic, community, and health plan factors associated with DMARD receipt among Medicare managed care enrollees. Design, Setting, and Participants We analyzed individual-level HEDIS data for 93 143 patients who were at least 65 years old with at least 2 diagnoses of RA within a measurement year (during 2005-2008). Logistic regression models with generalized estimating equations were used to determine factors associated with DMARD receipt and logistic regression was used to adjust health plan performance for case mix. Main Outcome Measures Receipt or nonreceipt of DMARD. Results The mean age of patients was 74 years; 75% were women and 82% were white. Overall performance on the HEDIS measure for RA was 59% in 2005, increasing to 67% in 2008 (P for trend <.001). The largest difference in performance was based on age: patients aged 85 years and older had a 30 percentage point lower rate of DMARD receipt (95% confidence interval [CI], -29 to -32 points; P<.001), compared with patients 65 to 69 years of age, even after adjusting for other factors. Lower percentage point rates were also found for patients who were men (-3 points; 95% CI, -5 to -2 points; P<.001), of black race (-4 points; 95% CI, -6 to -2 points; P<.001), with low personal income (-6 points; 95% CI, -8 to -5 points; P<.001), with the lowest zip code-based socioeconomic status (-4 points; 95% CI, -6 to 2 points; P<.001), or enrolled in for-profit health plans (-4 points; 95% CI, -7 to 0 points; P<.001); and in the Middle Atlantic region (-7 points; 95% CI, -13 to -2 points; P<.001) and South Atlantic regions (-11 points; 95% CI, -20 to -3 points; P<.001) as compared with the Pacific region. Performance varied widely by health plan, ranging from 16% to 87%. Conclusions Among Medicare managed care enrollees carrying a diagnosis of RA between 2005 and 2008, 63% received a DMARD. Receipt of DMARDs varied based on demographic factors, socioeconomic status, geographic location, and health plan. JAMA. 2011;305(5):480-486 www.jama.com
引用
收藏
页码:480 / 486
页数:7
相关论文
共 50 条
  • [41] Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis
    Neide Tomimura Costa
    Tatiana Mayumi Veiga Iriyoda
    Daniela Frizon Alfieri
    Andréa Name Colado Simão
    Isaias Dichi
    [J]. Inflammopharmacology, 2018, 26 : 1151 - 1164
  • [42] Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis
    Marguerie, L
    Flipo, RM
    Grardel, B
    Beaurain, D
    Duquesnoy, B
    Delcambre, B
    [J]. JOINT BONE SPINE, 2002, 69 (03) : 275 - 281
  • [43] Real-World Treatment Effectiveness of Disease-Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi J.
    Kim, Seoyoung C.
    [J]. ACR OPEN RHEUMATOLOGY, 2023, 5 (11) : 571 - 580
  • [44] Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients
    Xie, Fenglong
    Yun, Huifeng
    Levitan, Emily B.
    Muntner, Paul
    Curtis, Jeffrey R.
    [J]. ARTHRITIS CARE & RESEARCH, 2019, 71 (08) : 1004 - 1018
  • [45] Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis
    Boytsov, Natalie N.
    Bhattacharya, Ritupurna
    Saverno, Kim
    Dixon, Laurin
    Abbott, Paul L.
    Zhang, Xiang
    Gaich, Carol L.
    Nair, Radhika
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (08): : 879 - 887
  • [46] Disease-Modifying Antirheumatic Drug Initiation Among Patients Newly Diagnosed With Rheumatoid Arthritis
    Bonafede, Machaon
    Johnson, Barbara H.
    Shah, Neel
    Harrison, David J.
    Tang, Derek
    Stolshek, Bradley S.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (08): : SP279 - +
  • [47] Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis
    Nandi, Pradip
    Kingsley, Gabrielle H.
    Scott, David L.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (03) : 251 - 256
  • [48] Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis
    van Riel, PLCM
    Haagsma, CJ
    Furst, DE
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 1999, 13 (04): : 689 - 700
  • [49] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    [J]. JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655
  • [50] SAFETY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN JUVENILE RHEUMATOID-ARTHRITIS (JRA)
    KVIEN, TK
    HOYERAAL, HM
    SANDSTAD, B
    KASS, E
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1984, : 112 - 112